Life Technologies Launches Alliance to Evaluate Whole-Genome Sequencing for Guiding Cancer Treatment | GenomeWeb

By Julia Karow

This article, originally published June 3, has been updated from a previous version to include comments from Life Technologies CEO Greg Lucier.

A new initiative launched by Life Technologies last week, called the Genomic Cancer Care Alliance, plans to evaluate the utility of whole-genome sequencing for making treatment decisions for patients with a variety of difficult-to-treat cancers in a clinical trial.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.